comparemela.com

Latest Breaking News On - Syros pharmaceuticals company profile - Page 3 : comparemela.com

StockNews com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS)

StockNews.com initiated coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Get Rating) in a research report report published on Thursday. The firm issued a hold rating on the stock. Several other research firms have also weighed in on SYRS. JMP Securities reduced their price objective on shares of Syros Pharmaceuticals from $16.00 to $15.00 in […]

Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by Analysts at StockNews com

StockNews.com initiated coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Get Rating) in a report published on Thursday. The brokerage issued a hold rating on the stock. A number of other equities analysts have also recently weighed in on the stock. JMP Securities reduced their price target on shares of Syros Pharmaceuticals from $16.00 to […]

Brokerages Set Syros Pharmaceuticals, Inc (NASDAQ:SYRS) Target Price at $32 80

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Rating) has received a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokerages that […]

Royal Bank of Canada Raises Accenture (NYSE:ACN) Price Target to $340 00

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Rating) has earned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.